Marilena Vrana: Securing Sustainable Plasma Supply for Europe’s Growing Patient Needs
Marilena Vrana, Vice President at the Plasma Protein Therapeutics Association (PPTA) Europe, shared a post on LinkedIn:
“I was glad to join with my PPTA colleagues Anita Brikman, James Knowles and Halide Tuna, the 2026 IPFA/EBA Symposium on Plasma Collection and Supply in Leuven this week.
The discussions focused on both progress and ongoing challenges in meeting plasma need for the growing patient need for plasma-derived medicines, including immunoglobulins and other life-saving and life-enabling therapies.
During the exchanges with peers, I emphasized that ‘self-sufficiency’ should be addressed through a multi-stakeholder dialogue that includes patients and physicians. It must be viewed through the lens of European strategic autonomy – not only national capacity and self-sufficiency – and grounded in actual patient need.
While patient need is still not comprehensively recorded across all Member States, data show that it continues to grow steadily in Europe and globally, driven by improved diagnostic technologies, new indications, and evolving disease detection strategies.
Ensuring patients’ long-term peace of mind requires that we align policy ambition with real-world demand.
There is a clear opportunity for more aligned strategies across stakeholders – from streamlining contract fractionation arrangements to strengthening resilient supply chains that better serve patients in Europe and beyond.
Stronger public-private partnerships, supported by data and best practices, will be critical to closing availability gaps and advancing our collective responsibility to secure long-term sustainability of supply.
I look forward to continuing the dialogue at PPC2026 in Milan – an important checkpoint for our community – where the private sector’s role in strengthening Europe’s Resilience, Reach and Responsibility in plasma and plasma derived medicines will be further discussed.
Together, we can continue moving faster and further in delivering for all patients.”
Find more posts featuring Marilena Vrana on Hemostasis Today.
-
Apr 11, 2026, 13:51David McIntosh: Vital Plasma Derived Medicines – The Anomalous UK Scene
-
Apr 11, 2026, 13:47Samrawit Terefe: O Negative Blood Is the Universal Donor With Extreme Scarcity
-
Apr 11, 2026, 13:39Dheeraj Garg: Rethinking Cardiovascular Disease – A Cardiologist’s Perspective
-
Apr 11, 2026, 13:37Kushal Bhatia: Is The 4.5-Hour Thrombolysis Window Officially Outdated?
-
Apr 11, 2026, 13:35William Aird: Why Did Mammalian Red Blood Cells Give Up Their Nucleus?
-
Apr 11, 2026, 13:30Ken Kuang: Gravity Is Constant, But Your Vein Health Doesn’t Have to Be
-
Apr 11, 2026, 13:21Mascha Kern: Measuring Gender’s Role in Stroke and Migraine
-
Apr 11, 2026, 13:10Danique Steeghs: Key Findings from a Microfluidic Chemiluminescent Thrombin Generation Assay
-
Apr 11, 2026, 13:06Shanvi Mahi: A Validated Tool to Explore Lived Experiences After Stroke Rehabilitation